Gene editing technologies are rapidly evolving from experimental tools to promising therapeutic strategies in oncology.[3] CRISPR/Cas9 is a promising cancer treatment tool that allows disruption of oncogenes or restoration of tumor suppressor genes, which has led to significant tumor regression in preclinical studies.[1] Researchers at the ChristianaCare Gene Editing Institute have made major advances in the treatment of head and neck cancer using CRISPR editing of the NRF2 gene, which helps cancer patients resist chemotherapy.[2] Their study showed that editing the NRF2 gene in exon 4 reduced NRF2 levels by 90 percent and significantly increased the sensitivity of cancer cells to chemotherapy.[2] Despite promising results, there are still limitations including off-target side effects, delivery issues, and ethical issues that need to be resolved.[1] More exciting developments in gene therapy are expected in 2026, including trials for Huntington's disease and CRISPR treatment for high cholesterol.[4]